GGrantIndex
← Leaderboards

Laura-Isobel McCall

University Of Oklahoma

$3,552,176
Attributed
$5,011,426
Total exposure
5
Grants
5
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.2M · FY202025
$2M$1.5M$1M$500K$0
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$5,011,426 · 5

By mechanism

R01$4,126,682 · 3
R21$884,744 · 2

Top collaborators

Most similar at University Of Oklahoma

Same institution · by research overlap

Others in their field

Other Emerging Leaders on “Drug Development

Research focus

Drug DevelopmentBenznidazoleParasitesInfectionPharmaceutical PreparationsAntiparasitic AgentsTrypanosoma CruziMetabolomicsAffectEnsureMortalitySuccessTissuesPersonsPublic HealthCostAcylcarnitineAmericanClinicHeart DiseasesChagas DiseaseHeart DamageChronicHeart Failure

Grant awards (18)

Deciphering the mechanism of action of carnitine, a novel treatment for chronic Chagas disease$528,585
R01 · FY2025 · AI · contact PI
Novel single-cell mass spectrometry methods to assess the role of intracellular drug concentration and metabolism in antimicrobial treatment failure$420,914
R01 · FY2025 · AI · contact PI
An LCMS-guided bioanalytical approach for rational natural product library design and optimization$259,912
R01 · FY2025 · GM · contact PI
Deciphering the mechanism of action of carnitine, a novel treatment for chronic Chagas disease$466,493
R01 · FY2024 · AI · contact PI
Novel single-cell mass spectrometry methods to assess the role of intracellular drug concentration and metabolism in antimicrobial treatment failure$348,186
R01 · FY2024 · AI · contact PI
An LCMS-guided bioanalytical approach for rational natural product library design and optimization$265,497
R01 · FY2024 · GM · contact PI
Novel single-cell mass spectrometry methods to assess the role of intracellular drug concentration and metabolism in antimicrobial treatment failure$377,968
R01 · FY2023 · AI · contact PI
Deciphering the mechanism of action of carnitine, a novel treatment for chronic Chagas disease$291,099
R01 · FY2023 · AI · contact PI
An LCMS-guided bioanalytical approach for rational natural product library design and optimization$205,280
R01 · FY2023 · GM · contact PI
Deciphering the mechanism of action of carnitine, a novel treatment for chronic Chagas disease$130,557
R01 · FY2023 · AI · contact PI
An LCMS-guided bioanalytical approach for rational natural product library design and optimization$70,554
R01 · FY2023 · GM · contact PI
Novel single-cell mass spectrometry methods to assess the role of intracellular drug concentration and metabolism in antimicrobial treatment failure$1
R01 · FY2023 · AI · contact PI
Deciphering the mechanism of action of carnitine, a novel treatment for chronic Chagas disease$402,774
R01 · FY2022 · AI · contact PI
An LCMS-guided bioanalytical approach for rational natural product library design and optimization$358,862
R01 · FY2022 · GM · contact PI
Small molecule biomarkers of cardiac Chagas disease progression$234,971
R21 · FY2022 · AI · contact PI
Oral carnitine administration as a novel treatment for chronic-stage Chagas disease$232,500
R21 · FY2021 · AI · contact PI
Small molecule biomarkers of cardiac Chagas disease progression$223,523
R21 · FY2021 · AI · contact PI
Oral carnitine administration as a novel treatment for chronic-stage Chagas disease$193,750
R21 · FY2020 · AI · contact PI